AstraZeneca settles Seroquel patent litigation

SimonKennedy

LONDON (MarketWatch) -- AstraZeneca PLC s[: uk:azn]
AZN, -0.34%
said Friday that it has entered a settlement agreement in its U.S. Seroquel XR patent infringement litigation against Handa Pharmaceuticals LLC, regarding Handa's proposed generic version of Seroquel XR extended-release tablets. Under the settlement, AstraZeneca has granted Handa a license to enter the U.S. market with generic Seroquel XR in November, 2016, or earlier under certain circumstances. The drug is protected by patents and other exclusivity rights that range from March, 2012, to November, 2017.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information.
All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
Intraday data delayed at least 15 minutes or per exchange requirements.